SCHEMBL2933265

SCHEMBL2933265

CC1(C)C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccncc1O

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 16/20 0.66
TAS2R8 Q9NYW2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2939924 0.95 IGF1R (0.61) IGF1RTAS2R8
SCHEMBL2942422 0.89 IGF1R (0.68) IGF1R
SCHEMBL2941487 0.89 IGF1R (0.67) IGF1R
SCHEMBL2940794 0.89 IGF1R (0.67) IGF1RTAS2R8
SCHEMBL2935271 0.89 IGF1R (0.67) IGF1R
SCHEMBL2940155 0.89 IGF1R (0.67) IGF1RTAS2R8
SCHEMBL2934982 0.88 IGF1R (0.66) IGF1R
SCHEMBL2941430 0.88 IGF1R (0.66) IGF1R
SCHEMBL2943401 0.88 IGF1R (0.66) IGF1RTAS2R8
SCHEMBL2936682 0.88 IGF1R (0.63) IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP claimed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed